Clinical trial · no report yet · Phase 3
NCT06103864
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- NCT06103864 ↗
- Recruiting
- AstraZeneca
- 32 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 18 | |
| Podcasts | 11 | |
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Breast Cancer
- Interventions
- Dato-DXd; Durvalumab; Paclitaxel; Nab-paclitaxel; Gemcitabine; Carboplatin; Pembrolizumab
- Arms
- Dato-DXd + durvalumab · Experimental
- Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab · Active comparator
- Dato-DXd · Experimental
- Enrollment
- 625 (estimated)
- Primary outcomes
- Progression Free Survival (PFS)
- Sponsor
- AstraZeneca with Daiichi Sankyo
- Start
- Nov 23, 2023
- Primary completion
- Jul 28, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06103864 · updated Sep 25, 2026
Publications
linked from the registry- Schmid P, Oliveira M, O'Shaughnessy J, Cristofanilli M, Graff SL, Im SA, Loi S, Saji S, Wang S, Cescon DW, Hovey T, Nawrot A, Tse K, Vukovic P, Curigliano G. TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer. Ther Adv Med Oncol. 2025 Apr 17;17:17588359251327992. doi: 10.1177/17588359251327992. eCollection 2025. PubMed 40297626